Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SDF-1/CXCL12 CRISPR Activation Plasmid (h): sc-400268-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SDF-1/CXCL12 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- SDF-1/CXCL12 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by SDF-1/CXCL12 CRISPR Activation Plasmid (h) and SDF-1/CXCL12 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the CXCL12 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SDF-1/CXCL12 Antibody (P-159X): sc-74271
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SDF-1/CXCL12 CRISPR Activation Plasmid (h) | sc-400268-ACT | 20 µg | $397.00 | |||
SDF-1/CXCL12 CRISPR Activation Plasmid (h2) | sc-400268-ACT-2 | 20 µg | $397.00 |
CXCL12 (SDF-1/CXCL12) is a homeostatic CXC chemokine that signals primarily through CXCR4 and CXCR7/ACKR3 to regulate chemotaxis, cell survival, and tissue organization. This axis coordinates leukocyte trafficking, hematopoietic stem and progenitor cell retention in bone marrow niches, and vascular and neural development via downstream PI3K–AKT, MAPK/ERK, JAK/STAT, and calcium-dependent signaling. CXCL12 gradients shape tumor–stroma interactions, angiogenic programs, and metastatic tropism, and dysregulated CXCL12–CXCR4 signaling is implicated in inflammatory pathobiology and immune cell infiltration. As a microenvironmental cue, CXCL12 is frequently studied for its role in cell migration, adhesion, and niche remodeling across cancer, fibrosis, and immunology research settings.
SDF-1/CXCL12 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CXCL12 expression without altering the underlying DNA sequence.
SDF-1/CXCL12 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CXCL12 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CXCL12 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous SDF-1/CXCL12 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CXCL12 locus and enabling the study of SDF-1/CXCL12-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of SDF-1/CXCL12 pathway restoration in tumor cells with silenced or reduced CXCL12 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.